BioPharma
345 followers 21 artículos/semana
Kalaris to go public via reverse merger with AlloVir

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.

Fri Nov 8, 2024 19:07
Athira exploring strategic alternatives after Alzheimer’s failure

On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could take to “maximizing stockholder value.”

Fri Nov 8, 2024 19:07
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a narcolepsy drug and CDMO Avid Bioservices agreed to be taken private.

Fri Nov 8, 2024 18:39
What RFK Jr.’s influence on Trump could mean for pharma

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate if given a role in the incoming Trump administration.

Fri Nov 8, 2024 18:29
Moderna earnings beat forecasts, but analysts question whether sales spike will last

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Thu Nov 7, 2024 19:09
Sarepta scraps a Duchenne drug as gene therapy sales rise

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.

Thu Nov 7, 2024 18:29

Crea tu propia fuente de noticias

¿Listo para probarlo?
Comienza una prueba de 14 días, no es necesaria tarjeta de crédito.

Crear cuenta